Plain-English translation of NCT07413341 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which uses special particles to deliver genetic instructions directly into your immune cells. The goal is to reprogram your immune system to stop attacking your own body in people with hard-to-treat autoimmune diseases like lupus, Sjögren's syndrome, or systemic sclerosis. This is an early-stage study to see if the medication is safe and how well it works.
Many people with serious autoimmune diseases don't improve enough with standard treatments like steroids and immunosuppressive drugs. This trial is testing a completely new approach—using your own immune cells in a new way—to help patients whose disease keeps coming back or won't go away.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive an injection of the new medication and then be closely monitored to see how your body responds. The study will track how many patients are treated (starting with a small group and gradually increasing) to make sure the treatment is safe before giving it to more people. You would likely have multiple clinic visits for blood tests, imaging, and check-ups to monitor your disease activity and any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China